HBV'de Tedavi - EKMUD

GSBL-Karbapenemaz Üreten Gram-Negatif Mikroorganizma Enfeksiyonları:
Tedavi
18. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R,
Baquero F. Incidence and antimicrobial susceptibility of
Escherichia coli and Klebsiella pneumoniae with extended-spectrum
beta-lactamases in community- and hospital-associated
intra-abdominal infections in Europe:
results of the 2008 Study for Monitoring Antimicrobial
Resistance Trends (SMART). Antimicrob Agents
Chemother 2010;54:3043-6.
19. http://www.bsac.org.uk/
20. Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A; Spanish
Group for the Study of Pseudomonas; Spanish Network
for Research in Infectious Diseases. Activity of a new
antipseudomonal cephalosporin, CXA-101 (FR264205),
against carbapenem-resistant and multidrug-resistant
Pseudomonas aeruginosa clinical strains. Antimicrob
Agents Chemother 2010;54:846-51.
21. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H,
Chelly H, et al. Safety and efficacy of colistin compared
with imipenem in the treatment of ventilatorassociated
pneumonia: a matched case-control study. Intensive Care
Med 2007;33:1162-7.
22. Kaniga G, Flamm R, Tong SY, Lee M, Friedland I, Redman
R. Worldwide experience with the use of doripenem
against extended-spectrum-beta-lactamase-producing
and ciprofloxacin-resistant Enterobacteriaceae: analysis
of six phase 3 clinical studies. Antimicrob Agents
Chemother 2010;54:2119-24.
23. Karlı Ş, Ceran C, Genç İ, İnan A, Öztürk D, Taşdemir C ve
ark. Toplum ve hastane kaynaklı infeksiyonlardan izole
edilen GSBL pozitif Escherichia coli suşlarında tigesiklin
duyarlılığının araştırılması. ANKEM 2010;24:209-14.
24. Kayaalp O. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji.
7. baskı. Ankara: Güneş Kitabevi, 1994:894-9.
25. Köken G, Aşık G, Çiftçi İH, Çetinkaya Z, Aktepe OC,
Yılmazer M. Toplum kökenli üriner sistem enfeksiyonlu
etkeni Escherichia coli suşlarında fosfomisin trometamol
etkinliği. ANKEM 2008;22:23-27.
26. Landman D, Babu E, Shah N, Kelly P, Bäcker M, Bratu S,
et al. Activity of a novel aminoglycoside, ACHN-490,
against clinical isolates of Escherichia coli and Klebsiella
pneumoniae from New York City. J Antimicrob Chemother
2010;65:2123-7.
27. Linares L, Garcia-Goez JF, Cervera C, Almela M,
Sanclemente G, Cofán F, et al. Early bacteremia after solid
organ transplantation. Transplant Proc 2009;41:2262-4.
28. Linares L, Cervera C, Hoyo I, Sanclemente G, Marco F,
Cofán F, et al. Klebsiella pneumoniae infection in solid
organ transplant recipients: epidemiology and antibiotic
resistance. Transplant Proc 2010;42:2941-3.
29. Mathers AJ, Cox HL, Bonatti H, Kitchel B, Brassinga AK,
Wispelwey B, et al. Fatal cross infection by carbapenemresistant
Klebsiella in two liver transplant recipients.
Transpl Infect Dis 2009;11:257-65.
30. Öztürk CE, Kaya AD, Göçmen Ş, Arslan E. Toplum kaynaklı
idrar yolu infeksiyonu etkeni olan Escherichia coli
izolatlarının fosfomisin ile idrar yolu infeksiyonlarında sık
186
kullanılan antibiyotiklere duyarlılıkları. ANKEM
2008;22:81-84.
31. Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti
M, Katsiari M, Mainas E, et al. Tigecycline in the treatment
of infections from multi-drug resistant Gramnegative
pathogens. J Infect 2009;58:273-84.
32. Pullukcu H, Aydemir S, Tasbakan MI, Cilli F, Tunger A,
Ulusoy S. Susceptibility of Extended-Spectrum Beta-
Lactamase-Producing Escherichia coli Urine Isolates to
Fosfomycin, Ciprofloxacin, Amikacin and Trimethoprim-
Sulfamethoxazole. Turk J Med Sci 2008;38:175-80.
33. Pullukçu H, Aydemir Ş, Taşbakan MI, Sipahi OR, Çilli F,
Ulusoy S. Nitrofurantoinin idrar kültürlerinden soyutlanan
Escherichia coli suşlarına invitro etkinliği. İnfeksiyon
Dergisi 2007;21:197-200.
34. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir
S, Ulusoy S. Fosfomycin in the treatment of extended
spectrum beta-lactamase-producing Escherichia coli-related
lower urinary tract infections. Int J Antimicrob Agents
2007;29:62-5.
35. Pullukçu H, Ulusoy S. Tigesiklin. FLORA 2008;13(Ek 3):3-
16.
36. Rios FG, LunaCM, Maskin B, Saenz Valiente A, Lloria M,
Gando S, et al. Ventilatorassociated pneumonia due to
colistin susceptible-only microorganisms. Eur Respir J
2007;30:307-13.
37. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H,
Yamazhan T et al. Carbapenem versus fosfomycin tromethanol
in the treatment of extended-spectrum betalactamase-producing
Escherichia coli-related complicated
lower urinary tract infection. J Chemother 2010;22:355-
7.
38. Slocombe B, Basker MJ, Bentley PH, Clayton JP, Cole M,
Comber KR, et al. BRL 17421, a novel beta-lactam antibiotic,
highly resistant to beta-lactamases giving high and
prolonged serum levels in humans. Antimicrob Agents
Chemother 1981;20:38-46.
39. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA,
Goldstein EJ, Baron EJ et al. Diagnosis and management
of complicated intra-abdominal infection in adults and
children: guidelines by the Surgical Infection Society and
the Infectious Diseases Society of America. Surg Infect
(Larchmt) 2010;11:79-109.
40. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou
H, Kanellakopoulou K. Does the activity of the combination
of imipenem and colistin in vitro exceed the problem
of resistance in metallo-b-lactamase-producing Klebsiella
pneumoniae isolates? Antimicrob Agents Chemother
2009;53:2133-5.
41. Stachyra T, Levasseur P, Péchereau MC, Girard AM,
Claudon M, Miossec C, et al. In vitro activity of the
b-lactamase inhibitor NXL104 against KPC-2 carbapenemase
and Enterobacteriaceae expressing KPC carbapenemases.
J Antimicrob Chemother 2009;64:326-9.
42. Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline
and colistin combinations on imipenem-resistant
3. Türkiye EKMUD Bilimsel Platformu